anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present invention privilege application is directed to the medical sector and comprises a long-lasting, resorbable subcutaneous implant with extended release of pre-concentrated pharmacologically active substance in polymer for treatment of Parkinson&#39;s disease. The implant is inserted subcutaneously and has continuous release of the active ingredient for an extended period of time. This release aims to ensure an efficient, constant and prolonged serum level of the drug for the adjuvant treatment of Parkinson&#39;s disease. The implant of the present invention may have in its constitution only nicotinamide adenine dinucleotide (NADH), but is preferably formed of NADH particles homogeneously dispersed in a bioerodible and bioabsorbable polymer matrix. Implants can have any size, shape or structure that facilitates their manufacture and subcutaneous insertion, however, to obtain a more constant and uniform release of the active ingredient, it is necessary to use geometric shapes that maintain their surface area over time. The implant may have a polymeric coating membrane and the polymer used for the coating must be bioabsorbable and allow the passage of the active substance
PURPOSE:To provide a composition slightly digestable in a rumen juice and having the growth action on a living animal body by adding a methionine copolymer to a composition for the animal. CONSTITUTION:A composition for animals contains a methionine copolymer. The methionine copolymer itself or its mixture with a feed may be added to the composition. The methionine copolymer is added in an amount of approximately 0.05-1% as the methionine based on the whole amount of the feed. The methionine copolymer may be mixed with starch flour, wheat bran, soybean flour, rice bran, etc., also can be mixed as a powder form, or may be mixed with vitamins, minerals, bran, saccharides, proteins, etc., to give a pre-mix and subsequently molded into granules, tablets, syrups, etc. The composition may be, if necessary, further mixed with a dispersing agent, a stabilizer, a coloring agent, a perfume, an antiseptic, an antioxidant, etc. The composition for the animals is administered in an amount of &gt;=1mg, especially preferably 10-2000mg, per 10kg of the body weight of the animal.
PURPOSE: To obtain a cosmetic for skin coloring having excellent dispersing stability, giving fine and clear drawn line, having suitable adhesion excellent abrasion resistance, spreadable property, water resistance and sweat resistance and able to be easily washed. CONSTITUTION: This cosmetic for skin coloring contains at least water, pigment and a resin, at least one kind selected from a styrene-acrylic acid copolymer, a styrene-maleic acid copolymer, a styrene-alkyl acrylate copolymer and a styrene-alkyl maleate copolymer as the resin and at least a base selected from ammonia, amines and alkali (earth) metal hydroxide. The cosmetic may be further mixed with a clay-based thickener (e.g. natural smectite-based clay) in an amount of 0.1-10wt.%, an ultrafine thickener having a primary particle diameter of &lt;=50nm (e.g. silicon oxide or aluminum oxide) in an amount of 0.1-50wt.% or a polysaccharide thickener (e.g. xanthane gum or gellan gum) in an amount of 0.01-20wt.% as a thickener.
NEW MATERIAL:Isocholesterol alkyleneoxide addition compound of formula (R&lt;1&gt; is steroid skeleton of isocholesterol; R&lt;2&gt; is H or CH&lt;3&gt;; n is 5-100). EXAMPLE:Isocholesterol propyleneoxide addition compound. USE:Cosmetic base having lower melting point than isochlesterol, and desirable handleability. An emulsifying agent or a solubilizing agent having cell activating activity for cream, milky lotion, lipstick, hair tonic, etc. Also useful as an ointment base, cleansing cream, etc. PROCESS:The compound of the formula is prepared by reacting isocholesterol with an alkyleneoxide, if necessary in the presence of a catalyst such as KOH, at 100- 200 deg.C.
PURPOSE:To provide a skin cosmetic containing a thermally non-coagulable yolk, giving smooth feeling to the skin, having moisturizing effect, emollient effect and skin activating effect and imparting springiness and luster to the skin. CONSTITUTION:A thermally non-coagulable yolk is produced by selectively removing proteins participating in thermal coagulation from yolk of bird, e.g. chicken, quail, wild duck, turkey, etc., especially yolk of chicken&#39;s egg. For example, 1pt. of egg yolk is added with 3-5pts. of water (which may contain 3-25wt% ethyl alcohol) and is stirred to effect the selective coagulation of the above protein, the coagulum is separated from the mixture and the obtained yolk solution is optionally heat-treated at &gt;=80 deg.C to obtain the thermally non- coagulable yolk. The product is preferably condensed or dried and compounded to a skin cosmetic to obtain the objective skin cosmetic having the above effects. The amount of the non-coagulable protein is preferably 0.001-20wt%, especially 0.1-10wt% based on the whole composition in terms of solid.
The invention relates to a traditional Chinese medicine with a skin whitening function. The traditional Chinese medicine is composed of the following medicinal materials in parts by weight: 20 to 40 parts of bee pollen, 20 to 40 parts of pearl powder, 20 to 30 parts of dahurian angelica root, 20 to 40 parts of bletilla striata, 25 to 40 parts of white muscardine silkworm, 20 to 40 parts of rhizoma kaempferiae, 10 to 20 parts of towel gourd, 20 to 40 parts of rhizoma nardostachyos, 15 to 30 parts of safflower, 15 to 30 parts of seed of Job&#39;s tears, 20 to 40 parts of ampelopsis japonica, and 20 to 40 parts of almond. Because the components of the traditional Chinese medicine are all chosen from traditional Chinese medicines, the traditional Chinese medicine will not do harms to human skins. Rhizoma nardostachyos, rhizoma kaempferiae, and dahurian angelica root all have strong functions of penetrating and promoting human skin blood circulation, and can promote the skin cells&#39; metabolism. Bee pollen, pearl powder, bletilla striata, and white muscardine silkworm all have the skin whitening function. By adopting the traditional Chinese medicine mentioned above, the drug effect can be enabled to effectively penetrate the human skin, and achieves a good skin whitening effect.
Amyloid precursor protein (APP) dysfunction is a key feature in Alzheimer&#39;s disease (AD). The sortilin-related receptor 1 (SORLA) functions as a chaperone protein to APP and has reduced expression in AD brains. The APP and SORLA dysfunction results in homeostasis destabilization. Herpesviruses are suspected to be involved in AD pathogenesis. Using a strategic nucleotide BLAST to query SORL1 and APP nucleotide alignment on all Herpesviridae genomes identified similarity sequences from the Epstein-Barr virus and herpes simplex virus 2. The invention describes a treatment to alleviate EBV and HSV2-mediated neurodegeneration by delivering antisense oligonucleotides sequences that target the EBV and HSV2 non-coding sequences to block SORLA and APP disruption. The invention further describes methods to eradicate EBV infection by delivering inducible expression of antisense oligonucleotides targeting EBV genes or an inducible CRISPR/Cas gene-editing system, together with an expression construct encoding anti-apoptotic proteins or with anti-apoptotic proteins for the prevention of cell-mediated apoptosis.
The invention discloses a resveratrol analogue and a preparation method and application thereof to treatment of diseases related to aging and SIRTI enzyme activity. The resveratrol analogue disclosed by the invention has an eliminating effect on DPPH radical (DPPH.), superoxide anion radical (O2&lt;.-&gt;), hydroxide anion radical (OH.) and nitrogen peroxide radical (OHOO.) and has excellent antioxidation activity. Some derivatives of the resveratrol analogue are SIRTI enzyme activating agents while others are excellent SIRT1 enzyme inhibitors.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an atopic dermatitis improving composition containing plant extracts and a health promoting food containing them, and a method for production of the atopic dermatitis improving composition.  &lt;P&gt;SOLUTION: The atopic dermatitis improving composition contains extracts of root bark of elm, seeds of Cassia obtusifolia, whole herb of Taraxacum platycarpum and Prunus salicina. Each extract may contain 1-60 pts.wt. of an extract of root bark of elm, 1-60 pts.wt. of an extract of seeds of Cassia obtusifolia, 1-60 pts.wt. of an extract of whole herb of Taraxacum platycarpum and 1-60 pts.wt. of an extract of Prunus salicina, based on the concentrates to contain all the same amount of solid components.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Disclosed is a potentiated T-cell modulator (TCM) designed for treating the symptomology of the disease known as vitiligo. The TCM is obtained by means of a dialysable leucocyte extract from leucocyte cells that contain polypeptides equal to or less than 10,000 daltons, which extract comes specifically from Selachimorpha or shark spleen. The TCM can also reactivate the cells of an individual&#39;s immune system, enabling the organism to reactivate the cells responsible for skin pigmentation, i.e. melanocytes, and balance the production of melanin in the skin by means of this cell activation. The TCM has a potency of 10 12  leucocytes×mm 3  (potency being understood as the quantity of leucocytes and quality of the flat, round and innocuous cells), which potency is the quantity necessary to excite the leucocytes and optimise the chemical signals for producing white blood cells, which in turn produce melanocytes, which produce melanin. When coupled to the chemical signals of neurotransmitters to potentiate the signal, the TCM helps the neurotransmitters to re-establish the chemical signals that travel from the brain to the bone marrow, establishing the correct chemical signals to the melanocytes and thereby “ordering” them to begin producing melanin.
PURPOSE:The titled remover, obtained by incorporating a water swellable gel material, e.g. sodium montmorillonite, with a specific organic solvent and readily handleable without causing danger of causing a fire and no smell of the organic solvent in the form of a gel or paste. CONSTITUTION:A nail beautifying enamel remover containing (A) a water swellable gel material, e.g. sodium montmorillonite, and (B) a hydrophilic organic solvent, readily soluble in nitrocellulose and having &gt;=100 deg.C boiling point, e.g. lactone such as gamma-butyrolactone, acid amide such as tetramethylurea, ester such as methyl lactate or ethylene glycol monoacetate, or alcohol ether such as methyl cellosolve, in mixture. The amount of the component (A) to be incorporated in preferably 2-12%, particularly 5-7%. A fat or oil, e.g. squalane, is incorporated to protect the nail and a vitamin is incorporated to keep the health around the nail.
Device for applying or maintaining nitrite and/or nitrate cpds. (I) on a patient&#39;s skin comprises a porous layer (3) arranged between the skin (2) and at least the major portion of (I) being applied. Pref. a layer (4) acting as source of (I) is provided above the porous layer, esp. in galenical form such as ointment or suspension in an absorbant medium. The porous layer pref. consists of perforated, porous or microporous film and opt. a covering layer (6) which is impermeable to (I) and opt. also to air, is provided on the outside of the device. Pref. materials for the porous layer are polyamide fleece, perforated PVC film, viscose, acetate silk, cellulose-polyamide, cotton, polyurethane, cellulose and synthetic silk, and the outer cover is pref. PVC, polyethylene or lacquered and/or impregnated cotton. The devices are used in treatment of heart disorders, esp. to alleviate angina pectoris as a prophylactic against infarct. The duration of activity of (I) is increased and high initial serum concs. are prevented, so side-effects (nitrate headache&#39; and skin irritation) are minimised.
The invention discloses an application of a nucleic acid aptamer in preparing a medicament for treating Alzheimer&#39;s disease. The aptamer Ob2 which is combined with human AChE is screened out by SELEX technology, and the nucleotide sequence of the nucleic acid aptamer Ob2 is shown as SEQ ID NO. 2. In vitro test, Ob2 has the effect of inhibiting AChE activity. Through lateral ventricle administration, Ob2 can improve spatial learning and memory ability of an Alzheimer Disease (AD) model mouse, and reduce the contents of Abeta 40 and Abeta 42 in hippocampal and cortical layers and the number of senile plaque deposits of the mouse. Due to the high specificity and high binding property of the aptamer, the aptamer aiming at human AChE is a powerful tool for detecting AChE in vitro and in vivo, and is expected to be developed into a novel AChE inhibitor for treating AD and other diseases. Provides a research foundation for the development of novel specific AChE inhibition and provides a new method and a new thought for AD treatment.
The application provides an automatic doctor&#39;s advice task execution method, equipment and medium for inpatients, and belongs to the technical field of intelligent robots. The method receives an order task execution request; based on the doctor&#39;s advice task execution request and the position of the ward to be nursed corresponding to the patient to be nursed, a corresponding initial nursing planning map is determined. A number of planned care paths corresponding to the at least one blood pressure measurement robot are acquired. It is determined whether there is another order task execution request for each planned care path that conflicts with an order task execution request corresponding to the patient to be cared for. If not, updating each planned nursing path according to the corresponding planned nursing paths and the initial nursing planning map so as to add the nursing arrival path corresponding to the position of the ward to be nursed to the planned nursing path, so that the blood pressure measuring robot sequentially executes doctor&#39;s advice tasks corresponding to the planned nursing paths through the planned nursing paths. By the method, labor cost in blood pressure measurement task is reduced.
&lt;P&gt;PROBLEM TO BE SOLVED: To develop a method for promoting penetration of a water-soluble medicine by applying it from the outside of the skin without utilizing a direct current electric source (cell) though it is a method for promoting penetration of a medicine by utilizing a potential gradient.  &lt;P&gt;SOLUTION: A method for promoting penetration of a medicine ionizing in an aqueous solution is provided. The method comprises a step for applying the medicine to the skin, and a subsequent step for applying to the skin a mixed liquid, with the medicine, of a particle having a charge repelling the ionized medicine in the aqueous solution. The medicine can be 4-methoxysalicilic acid or a salt thereof in the method. The kit comprises the mixture, with the particle, of the medicine having a negative charge in an aqueous solution and the medicine, and is used for carrying out the method by applying the aqueous solution of the medicine to the skin after a treatment for temporarily decreasing barrier functions of the skin and subsequently applying the aqueous solution of the mixture to the skin.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Low dose radiation, including conversion electron energy induces apoptosis in peripheral macrophages and CNS microglia. The transport of Sn-117m, a conversion electron emitter has been shown to be deliverable into the CNS across the blood-brain-barrier (BBB). The receptor for advanced glycation end products (RAGE) is a multi-ligand receptor member of the immunoglobulin super family which is able to bind A13 peptide and 13-sheet fibrils. It is expressed in endothelial cells, smooth muscle cells, microglia and neurons, and is implicated in the transport of A13 through the BBB, oxidative stress-mediated neurotoxicity, and adverse microglia inflammatory responses. The interaction between RAGE and its ligands is thought to result in pro-inflammatory gene activation. Enhanced levels of RAGE ligands in Alzheimer&#39;s disease are thought to contribute to the cause of this disorder. Embodiments of the invention use the RAGE multi-ligand site as an anchoring loci for a conversion electron emitting compound rather than as a receptor to intrinsically activate or block inflammation through the RAGE intracellular cascade through activation of the RAGE cytoplasmic tail (ctRAGE) and mammalian diaphanous 1 (DIAPH1).
PURPOSE:To provide an excellent antiepileptic agent based on the central acting mechanism, and containing diaminodiphenylsulfone which is known as an antibacterial agent, a remedy for Hansen&#39;s disease, etc. CONSTITUTION:The objective antiepileptic agent can be prepared by using the diaminodiphenylsulfone of formula as an active component. It has been found that, in the compound of formula, p,p&#39;-diaminodiphenylsulfone has excellent antiepileptic activity based on the central acting mechanism which is absolutely different from the mechanism of the known antibacterial effect. The compound of formula can be used in the form of tablet, powder, injection, etc. by ordinary prescription. It is administered by oral administration, injection, etc. Dose: preferably 10-300mg/60kg daily.
The present invention relates to a kind of medicament for the treatment of vulvovaginal candidiasis, it is made up of the material of following weight portion: little contribution 10-20 part, Herba seu Radix Calanthes 5-15 part, Herba Sheareriae 10-20 part, mountain Pericarpium Citri Reticulatae Viride 10-20 part, Semen Iridis 1-10 part, Herba Dodartiae Orientalis 20-30 part, Herba sei Radix Crotalariae tetragonae 1-10 part, Scobis Diospyroris Ebeni 5-15 part, Camellia sinensis O. Ktze. Var. macrophylla Sieb. 10-20 part, father-in-law&#39;s ripple 1-10 part, Folium Viticis Negundo 20-30 part, snow medicine 10-20 part, nine pipe blood 5-15 parts, Fructus polygoni sieboldii 10-20 part, Herba Lespedezae Cuneatae 20-30 part, Physalis alkekengi L. var. francheti (Mast.) Makino 5-15 part, Herba Violae Hortensis 5-15 part, Herba Pentanematis Indici 20-30 part, Fructus Vaccinii Bracteati 5-15 part, Radix Glycyrrhizae 1-10 part.Pharmaceutical treatment vulvovaginal candidiasis of the present invention is evident in efficacy, and easy and simple to handle, use safety, toxic and side effects are few, clinical be easy to promote, patient be easy to accept.
PURPOSE:To obtain a new platinum complex, capable of manifesting excellent antitumor effects, having high safety, good in water solubility and useful as a therapeutic agent for malignant tumor. CONSTITUTION:This platinum complex is of formula I (R&lt;1&gt; to R&lt;3&gt; are each H, a straight-chain or a branched chain alkyl, etc.; X is a halogen or two groups X may be bound to form a malonic acid residue, with the proviso that R&lt;1&gt; to R&lt;3&gt; are not simultaneously H), e.g. cis-dichloroammine (N-methylhydroxylamine) platinum(II). The complex is obtained by reacting, e.g. a Pt compound of formula II with potassium iodide in water or a mixture solution of water with ethanol, then reacting the resultant product with an amine of the formula R&lt;1&gt;NHOR&lt;2&gt; according to a method for using a solution prepared by dissolving the hydrochloride of the amine in an alkaline hydroxide solution, then suspending the resultant compound of formula III in water, adding silver nitrate to the prepared suspension, carrying out the reaction and finally reacting the produced aqueous solution of a diaquo complex of formula IV with a dilute hydrochloric acid, malonic acid, etc.
PROBLEM TO BE SOLVED: To provide a C-S lyase activity inhibitor, a deodorant agent and a hircismus generation-suppressing method, with hircismus generation-suppressing effect being high.SOLUTION: A C-S lyase inhibitor comprises one or more compound selected from a carbonyl compound and an alcohol compound represented by the general formula (1). A hircismus generation-suppressing composition and a deodorant agent contain the C-S lyase inhibitor. In a hircismus generation suppressing method, a fixed amount of the C-S lyase inhibitor is applied to the axillae. [X represents O or OH, the broken-line represents a double bond if X is O and represents a single bond if X is OH. R, R&#39;, R, Rand Rrepresent H, OH, an alkyl group, an alkenyl group or an alkenyloxy group. Rand R, Rand R, Rand Rmay form a cyclic structure with an adjacent C atom. However, when X is O, R&#39; does not exist.]
A computer-implemented method, computer program product and computer system (100) for predicting the risk of a patient (10) to develop an atherosclerotic cardiovascular disease within a predefined time interval. The system receives a current set of risk factors associated with the risk of atherosclerotic plaque build-up in the patient&#39;s arteries. The current set comprises a set of human-curated risk factors covering multiple biological levels of the patient to capture the potential interactions or correlations detected between molecules in different biological levels. A predictor (110) receives the current set as test input to, wherein the predictor has been trained with a training data set (300) including a number of training patient records. The training data set includes risk factor training values (310 to 350) corresponding to the same set of variables as included in the test input of said patient, (10) and serving as training inputs. The training data set further includes atherosclerotic cardiovascular disease outcomes (390) of the training patients (90) serving as ground truth. The risk factor training values and the outcomes were obtained over a training data collection period of at least the length of the predefined time interval. None of the training patients (90) has shown an atherosclerotic cardiovascular disease outcome up to the beginning of the training data collection period. The predictor (110) provides, in response to the test input, a predicted risk (111) for developing an atherosclerotic cardiovascular disease for said patient (10) within the predefined time interval.
PROBLEM TO BE SOLVED: To obtain a cosmetic, excellent in UV-A absorptivity, excellently familiar with skin, capable of manifesting an excellent preservation stability by formulating a benzalhydantoin-based ultraviolet absorber having extremely small solubility. SOLUTION: This cosmetic is obtained by formulating the powder of a 5-(3,4- dialkoxybenzal)hydantoin of the formula (R&lt;1&gt; and R&lt;2&gt; are each a 1-3C alkyl) and/or the power obtained by carrying out a coating treatment of a power for cosmetics (e.g. a pigment) with the compound of the formula as an ultraviolet absorber. The compound of the formula can be obtained by condensing a 3,4-dialkoxybenzaldehyde with hydantoin using a basic catalyst. The powder formulated as an ultraviolet absorber preferably has an average particle diameter of 0.001-100 μm, and the mixing amount of the powder is preferably 0.01-10 wt.%. As a result, the cosmetic having no problem of crystal precipitation, etc., even if preserved for a long term, and excellent in functionality and form stability is expected.